By Budi Oetomo Narendra 
Aging, an intricate biological process marked by progressive functional decline, affects individuals at varying rates but remains an inescapable universal phenomenon. New research from Stanford Medicine, published recently in the esteemed journal Science, has illuminated a crucial breakdown within the immune system that appears to be a significant driver of systemic aging. Conducted in both laboratory mice and human cells, this groundbreaking study points to a specific failure in how the body’s immune system manages cellular waste, offering a novel target for potential interventions to slow age-related deterioration and extend healthy lifespan.
The Immune System’s Critical Housekeepers: A Deeper Look into Macrophage Decline
The core of the Stanford discovery centers on tissue-resident macrophages, a specialized type of immune cell. These long-lived cells establish permanent residency within organs during fetal development, adapting to perform highly specific functions unique to their location throughout an organism’s life. Among their most vital roles is the disposal of defunct and senescent cells—a cellular "garbage collection" service essential for maintaining tissue health and preventing inflammation. The research, led by senior author Katrin Andreasson, MD, the Edward F. and Irene Thiel Pimley Professor in Neurology and Neurological Sciences, and lead author Jessy Tan, PhD, an instructor in neurology, found that with advancing age, these macrophages become increasingly inefficient at clearing another class of immune cells known as neutrophils. This decline in macrophage function, the scientists posit, is not merely a localized issue but contributes significantly to the process of aging throughout the entire body.
Neutrophils are the most abundant type of white blood cell and serve as the immune system’s frontline responders, rapidly deploying to sites of infection or injury. Produced in the bone marrow, they circulate in the bloodstream, constantly patrolling for bacterial, viral, and fungal threats. Their operational lifespan is remarkably brief, typically ranging from 12 to 24 hours. After fulfilling their duties or simply reaching the end of their short lives, roughly 90% of circulating neutrophils are directed to organs like the liver, spleen, and bone marrow, where they are efficiently removed by other immune cells, primarily macrophages. This disposal mechanism is critically important, especially as an organism ages. In older animals and humans, neutrophils that have not encountered pathogens often enter a state of senescence—a dysfunctional condition where they can release harmful chemicals, damage nearby healthy cells, and actively promote chronic inflammation. Compounding the problem, the number of circulating neutrophils tends to increase with age, and a growing proportion of them become senescent, creating a significant burden on the body’s clearance mechanisms. "Senescent neutrophils are killing our tissues," Dr. Andreasson emphasized, underscoring the vital need for their effective removal. "Clearance of these cells is essential for preventing chronic inflammation."
Macrophages are the primary cellular custodians tasked with this monumental cleanup effort. Beyond their role as cellular waste collectors, these versatile immune cells are instrumental in fighting pathogens, coordinating responses from other immune cells, and releasing growth factors crucial for tissue repair. Dr. Andreasson likened them to the body’s "garbage collection crew," noting that a substantial portion of this "garbage" consists of these defunct neutrophils—an estimated 100 billion of which require clearance every single day. The research highlighted that tissue-resident macrophages specifically target senescent neutrophils, which begin displaying "kill me now" signals on their surfaces mere hours after entering the bloodstream.
The Inflammatory Feedback Loop: PGE2 and EP2’s Role in Age-Related Decline
The critical turning point in this age-related cellular cleanup failure appears to be an inflammatory feedback process involving prostaglandins, a group of lipid compounds with hormone-like effects. One specific type, prostaglandin E2 (PGE2), is known to exert diverse effects on cells depending on the specific receptors present on their surfaces. The Stanford team focused on a particular receptor for PGE2, known as EP2, which is highly abundant on tissue-resident macrophages and is a strong promoter of inflammation.
PGE2 production naturally escalates in response to various stressors, including infection, injury, and exposure to toxic substances. Crucially, as the body ages, the production of PGE2 also rises substantially. Simultaneously, tissue-resident macrophages develop higher concentrations of the EP2 receptor. This dual increase sets the stage for a detrimental feedback loop: heightened PGE2 activity repeatedly stimulates EP2 receptors on tissue-resident macrophages. The new study found that this incessant stimulation progressively weakens the macrophages’ ability to effectively engulf and digest senescent neutrophils. The consequence is a dangerous accumulation of these harmful, senescent neutrophils in the bloodstream and various tissues, fueling the systemic chronic inflammation often observed in aging—a phenomenon termed "inflammaging." This finding builds upon Dr. Andreasson’s earlier work, which showed in a 2021 Nature study that tissue-resident macrophages themselves become more vulnerable to inflammation with age and can then contribute to it, further exacerbating the problem. The team also previously observed that the energy metabolism of these macrophages deteriorates with age, a decline now strongly linked to the EP2 pathway. "Once that starts, there’s a steady decline in a macrophage’s performance," Dr. Andreasson explained, adding, "We’ve shown that when tissue-resident macrophages don’t have EP2 on their surfaces anymore or when that receptor is plugged up by a drug, this decline doesn’t happen."
Experimental Validation: A Youthful Reversal in Mice
To rigorously investigate the EP2 receptor’s precise role, Dr. Andreasson’s laboratory engineered mice in which the EP2 gene could be selectively deleted in tissue-resident macrophages at a chosen time point. The results were striking: removing EP2 effectively restored the macrophages’ ability to dispose of neutrophils, completely reversing the age-related disruption caused by PGE2.
The researchers conducted a comprehensive comparison, studying three groups of mice:
- Younger normal mice: Aged 6 to 8 months, roughly equivalent to late adolescence or early adulthood in humans.
- Older normal mice: Aged 23 to 25 months, comparable to humans in their 60s or 70s.
- Older mice with deleted EP2: Nearly identical to the second group, but with the EP2 gene deleted in their tissue-resident macrophages during their "teenage" years (4 to 6 months old).
The findings were remarkable. In normal older mice, the researchers identified 71 blood proteins whose levels had significantly altered with age. Astonishingly, in older mice whose tissue-resident macrophages lacked EP2, 59 of these 71 proteins remained at youthful levels. Many of these beneficial changes were traced back to the liver, a critical metabolic organ rich in tissue-resident macrophages. "The liver is one of the body’s most tissue-resident-macrophage-enriched organs and a major contributor to aging-related changes in blood chemistry," Dr. Andreasson noted. "It’s the central organ determining the body’s metabolic rate."
Furthermore, normal older mice exhibited an accumulation of senescent neutrophils in the liver, spleen, and bone marrow, with smaller increases observed across numerous other organs. In stark contrast, older mice whose tissue-resident macrophages lacked EP2 maintained the lower, youthful levels of neutrophils in their organs. These mice also presented with visibly younger, leaner, and more physically fit characteristics compared to their age-matched controls. They displayed less visceral fat—a harmful type of fat associated with metabolic disease—and retained more muscle mass. Their performance on a battery of tests designed to measure the function of several organs matched that of young mice, suggesting a broad, systemic rejuvenation.
Memory, Strength, and Inflammation: A Multifaceted Improvement
The benefits of disabling EP2 extended beyond mere physical markers. Removing EP2 from tissue-resident macrophages dramatically reduced inflammation in the blood and in specific organs, including the liver, colon, heart, kidney, and the hippocampus—a brain region critically involved in memory formation and spatial navigation.
On tests of physical prowess, older mice without EP2 performed on par with younger animals, exhibiting superior speed, balance, and forelimb grip strength compared to their aging counterparts. Their cognitive functions also remained robust. These mice navigated mazes and remembered previously encountered objects almost as effectively as young mice, significantly outperforming similarly aged mice whose EP2 receptors continued to function normally. These results collectively underscore the profound, multi-systemic impact of targeting this single immune receptor.
From Mice to Humans: Promising Parallels and Translational Potential
The translational potential of these findings was further bolstered by an analysis of human data. The researchers examined a comprehensive database containing information on different cell types from young, old, and diseased human livers. They discovered patterns strikingly similar to those observed in the mice: older human livers showed increased neutrophil accumulation, a greater proportion of senescent neutrophils, evidence of declining tissue-resident macrophage function, and elevated EP2 activity. These detrimental changes were even more pronounced in diseased human livers, suggesting a direct link to pathological conditions. Dr. Andreasson highlighted the significance of these findings, noting that it was "the first time these changes had been observed in human cells." This critical validation in human tissue strengthens the argument that the identified immune pathway is relevant to human aging and age-related diseases.
The Quest for a Targeted Therapy: Navigating the Challenges of Drug Development
While the findings are profoundly encouraging, the path to a human therapeutic remains complex. Currently, no approved drug exists that can selectively shut down EP2 activity. Although several medications affect PGE2, a broad suppression of PGE2 is not a viable strategy. Nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin reduce PGE2 production, which explains their efficacy in reducing pain, fever, swelling, and redness—the classic signs of inflammation. However, these medications also interfere with other prostaglandins that perform essential physiological functions. Moreover, PGE2 itself can exert beneficial effects when interacting with receptors other than EP2. The ideal therapeutic approach, therefore, would be to specifically target the EP2 receptor responsible for the harmful inflammatory response, without disrupting the broader prostaglandin system.
To explore this targeted approach, the scientists administered an experimental drug that selectively inhibits EP2 to otherwise normal 22-month-old mice for a period of two months. The treatment yielded promising results: both total neutrophil levels and the number of senescent neutrophils in these older mice were brought closer to youthful levels. Further experiments in cell cultures confirmed that while aging impaired the ability of tissue-resident macrophages to engulf and digest worn-out neutrophils, the EP2-blocking drug significantly restored this crucial function.
The development of a safe and selective drug that blocks EP2 without interfering with earlier processes, such as general PGE2 production, is now a priority for the research team. This journey from laboratory discovery to a clinically approved drug is typically long and arduous, involving extensive preclinical testing, multiple phases of human clinical trials, and rigorous regulatory review. However, the potential benefits—improving the body’s ability to remove aging neutrophils and thereby slowing age-related deterioration—are immense.
Broader Impact on Geroscience and Public Health
This research represents a significant leap forward in the field of geroscience, which seeks to understand the fundamental biological mechanisms of aging with the goal of extending "healthspan"—the period of life spent in good health—rather than merely lifespan. By identifying a specific, targetable immune pathway that drives systemic aging, the Stanford team has opened a new avenue for developing preventative and therapeutic strategies against a wide array of age-related diseases, including neurodegenerative disorders, cardiovascular disease, and metabolic dysfunction, all of which are exacerbated by chronic inflammation.
The global population is aging rapidly, posing unprecedented challenges to healthcare systems and economies worldwide. Chronic diseases associated with aging place an enormous burden on individuals, families, and societies. Discoveries like those from Stanford Medicine offer a beacon of hope, suggesting that it may be possible to intervene in the aging process itself, rather than solely treating individual age-related ailments as they arise. This paradigm shift could lead to healthier, more vibrant later years for millions, transforming the landscape of public health in the 21st century.
The study was a collaborative effort, with a researcher from the University of Munster in Germany also contributing. The work received substantial funding from multiple prestigious sources, including the National Institutes of Health (grants 1RF1AG080742, 1RF1AG070839, and P30AG066515), the American Heart Association, the Phil and Penny Knight Initiative for Brain Resilience (at the Wu Tsai Neurosciences Institute), Stanford University, the Arc Institute, and the Chan-Zuckerberg Biohub. Part of the experimental work was conducted at the Neurosciences Preclinical Imaging Community Laboratory at the Wu Tsai Neurosciences Institute, underscoring the collaborative and interdisciplinary nature of this pivotal research.
